CME credits: 0.50 Valid until: 04-08-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/ This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients. 

ReachMD CME

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 1: Detection and Diagnosis

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/horizon-strategies-surgical-success-durable-anti-vegf-delivery-namd-and-dme/12660/ The quest for durable VEGF-suppression in neovascular AMD and diabetic macular edema has led to significant advances in the operating room for surgical retina specialists. What are these new methods, and what do surgeons need to know to ensure a successful procedure? Listen to pro tips from Drs. Carl Awh and Peter Campochiaro and see demonstrations of the new techniques. How will your patients benefit from the introduction of durable VEGF suppression into clinical practice? 

On the Horizon: Strategies for Surgical Success of Durable Anti-VEGF Delivery in nAMD and DME

CME credits: 0.50 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/horizon-achieving-durable-vegf-suppression-namd-and-dme/12662/ One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use? Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice. 

On the Horizon: Achieving Durable VEGF Suppression in nAMD and DME

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/updates-head-and-neck-cancer-treatment-integrating-checkpoint-inhibitor-therapy-improve-outcomes/12701/ Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients. 

Updates in Head and Neck Cancer Treatment: Integrating Checkpoint Inhibitor Therapy to Improve Outcomes

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/act-fast-case-study-postexposure-influenza-prophylaxis/12734/ Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment. 

Act Fast: A Case Study on Post-Exposure Influenza Prophylaxis

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/future-narcolepsy-therapy-its-likely-impact-disease-burden-and-patient-outcomes/12743/ While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy. 

The Future of Narcolepsy Therapy: Its Likely Impact on Disease Burden and Patient Outcomes

CME credits: 0.25 Valid until: 28-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/hdfnnew-understandings-risk-diagnosis-and-therapeutic-approaches/12710/ Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical. Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.

HDFN: New Understandings of Risk, Diagnosis, and Therapeutic Approaches

CME credits: 1.25 Valid until: 27-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/abcs-ctd-pah-algorithms-team-based-approach-and-combination-therapy/12739/ John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.

The ABCs of CTD-PAH: (A)lgorithms, Team-(B)ased Approach, and (C)ombination Therapy

CME credits: 0.25 Valid until: 26-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12718/ More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!

Clinician’s Update on Omega-3s in ASCVD Risk Reduction

CME credits: 0.50 Valid until: 16-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/evolving-landscape-chronic-lymphocytic-leukemia-selecting-and-managing-targeted-therapy/12643/ Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings. In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.

The Evolving Landscape of Chronic Lymphocytic Leukemia: Selecting and Managing Targeted Therapy

CME credits: 0.25 Valid until: 15-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/raasi-therapy-diabetes-and-hyperkalemia-halting-therapy-not-only-option/12714/ In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy. 

RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option

CME credits: 0.25 Valid until: 14-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/riding-wave-change-cervical-cancer-screening-managing-patients-light-risk-using-extended-genotyping/12697/ Updated cervical cancer screening guidelines were published by both the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS). Dr. Lee Shulman leads a discussion with Dr. Anna-Barbara Moscicki on the recent guidelines, the range of cervical cancer screening tests, and the impact on risk stratification and patient management.

Riding the Wave of Change in Cervical Cancer Screening: Managing Patients in Light of Risk Using Extended Genotyping

CME credits: 0.25 Valid until: 13-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/act-fast-understanding-flu-prevention-and-treatment-risk-populations/12717/ Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.

Act Fast: Understanding Flu Prevention and Treatment in At-Risk Populations

CME credits: 0.50 Valid until: 09-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/changing-treatment-paradigms-in-type-1-diabetes-role-of-anti-cd3-targeted-therapy-screening-for-islet-autoantibodies-in-children-and-adolescents-to-preventdelay-t1d/12695/ Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes. 

Changing Treatment Paradigms in Type 1 Diabetes: Role of Anti-CD3 Targeted Therapy - Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D

hubhopper

ReachMD CME

hubhopper